|Mateusz Łukaszyk, Ewelina Jastrzębska, Ziemowit Ziętkowski, Anna Bodzenta-Łukaszyk|
Asthma is a chronic inflammatory disease of the airways. Nearly 60% of asthma cases have allergic background. About 5-10% of patients treated for asthma do not respond well to standard treatment suggested by GINA 2006 guidelines. The article reviews the anti-IgE therapy for patients with severe/difficult asthma as well as points out the prospects of treatment with new biological drugs now being in 2nd and 3rd phase of clinical trials, which may play a significant role in severe asthma treatment in the near future.
keywords: astma ciężka/ trudna, omalizumab, mepolizumab,lebrikizumab, severe/difficult asthma, omalizumab, mepolizumab,lebrikizumab
pages: from 86 to 90
|estimated time of download (248 kB)|